240 related articles for article (PubMed ID: 27564116)
1. Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry.
Li J; Xie H; Li A; Cheng J; Yang K; Wang J; Wang W; Zhang F; Li Z; Dhillon HS; Openkova MS; Zhou X; Li K; Hou Y
Oncotarget; 2017 Jul; 8(29):46834-46845. PubMed ID: 27564116
[TBL] [Abstract][Full Text] [Related]
2. Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery.
Zhang F; Zhang Y; Ke C; Li A; Wang W; Yang K; Liu H; Xie H; Deng K; Zhao W; Yang C; Lou G; Hou Y; Li K
Metabolomics; 2018 Apr; 14(5):65. PubMed ID: 30830339
[TBL] [Abstract][Full Text] [Related]
3. Prediction of advanced ovarian cancer recurrence by plasma metabolic profiling.
Zhang H; Ge T; Cui X; Hou Y; Ke C; Yang M; Yang K; Wang J; Guo B; Zhang F; Lou G; Li K
Mol Biosyst; 2015 Feb; 11(2):516-21. PubMed ID: 25424060
[TBL] [Abstract][Full Text] [Related]
4. Metabolic profiling and novel plasma biomarkers for predicting survival in epithelial ovarian cancer.
Xie H; Hou Y; Cheng J; Openkova MS; Xia B; Wang W; Li A; Yang K; Li J; Xu H; Yang C; Ma L; Li Z; Fan X; Li K; Lou G
Oncotarget; 2017 May; 8(19):32134-32146. PubMed ID: 28389631
[TBL] [Abstract][Full Text] [Related]
5. [Discrimination and clinical value of plasma metabolomic profiles in multidrug resistant epithelial ovarian cancer].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):896-902. PubMed ID: 29262505
[No Abstract] [Full Text] [Related]
6. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry.
Zhang T; Wu X; Yin M; Fan L; Zhang H; Zhao F; Zhang W; Ke C; Zhang G; Hou Y; Zhou X; Lou G; Li K
Clin Chim Acta; 2012 May; 413(9-10):861-8. PubMed ID: 22309680
[TBL] [Abstract][Full Text] [Related]
7. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform.
Fan L; Zhang W; Yin M; Zhang T; Wu X; Zhang H; Sun M; Li Z; Hou Y; Zhou X; Lou G; Li K
Acta Oncol; 2012 Apr; 51(4):473-9. PubMed ID: 22283470
[TBL] [Abstract][Full Text] [Related]
8. Saturated fatty acids as possible important metabolites for epithelial ovarian cancer based on the free and esterified fatty acid profiles determined by GC-MS analysis.
Yin R; Yang T; Su H; Ying L; Liu L; Sun C
Cancer Biomark; 2016 Sep; 17(3):259-269. PubMed ID: 27802202
[TBL] [Abstract][Full Text] [Related]
9. Large-scale profiling of metabolic dysregulation in ovarian cancer.
Ke C; Hou Y; Zhang H; Fan L; Ge T; Guo B; Zhang F; Yang K; Wang J; Lou G; Li K
Int J Cancer; 2015 Feb; 136(3):516-26. PubMed ID: 24895217
[TBL] [Abstract][Full Text] [Related]
10. Wide-Targeted Metabolome Analysis Identifies Potential Biomarkers for Prognosis Prediction of Epithelial Ovarian Cancer.
Hishinuma E; Shimada M; Matsukawa N; Saigusa D; Li B; Kudo K; Tsuji K; Shigeta S; Tokunaga H; Kumada K; Komine K; Shirota H; Aoki Y; Motoike IN; Yasuda J; Kinoshita K; Yamamoto M; Koshiba S; Yaegashi N
Toxins (Basel); 2021 Jun; 13(7):. PubMed ID: 34209281
[TBL] [Abstract][Full Text] [Related]
11. Selection of small plasma peptides for the auxiliary diagnosis and prognosis of epithelial ovarian cancer by using UPLC/MS-based nontargeted and targeted analyses.
Lu X; Li Y; Xia B; Bai Y; Zhang K; Zhang X; Xie H; Sun F; Hou Y; Li K
Int J Cancer; 2019 Apr; 144(8):2033-2042. PubMed ID: 30114318
[TBL] [Abstract][Full Text] [Related]
12. SPME-LC/MS-based serum metabolomic phenotyping for distinguishing ovarian cancer histologic subtypes: a pilot study.
Olkowicz M; Rosales-Solano H; Kulasingam V; Pawliszyn J
Sci Rep; 2021 Nov; 11(1):22428. PubMed ID: 34789766
[TBL] [Abstract][Full Text] [Related]
13. Metabolic phenotyping for monitoring ovarian cancer patients.
Ke C; Li A; Hou Y; Sun M; Yang K; Cheng J; Wang J; Ge T; Zhang F; Li Q; Li J; Wu Y; Lou G; Li K
Sci Rep; 2016 Mar; 6():23334. PubMed ID: 26996990
[TBL] [Abstract][Full Text] [Related]
14. Targeted metabolomic profiling of low and high grade serous epithelial ovarian cancer tissues: a pilot study.
Garg G; Yilmaz A; Kumar P; Turkoglu O; Mutch DG; Powell MA; Rosen B; Bahado-Singh RO; Graham SF
Metabolomics; 2018 Nov; 14(12):154. PubMed ID: 30830441
[TBL] [Abstract][Full Text] [Related]
15. Serum lipid profiling analysis and potential marker discovery for ovarian cancer based on liquid chromatography-Mass spectrometry.
Wang Y; Wang Y; Chen C; Ren F; Cao R; Wang Y; Han P; Zhang X; Xu C; Liu X; Xu G
J Pharm Biomed Anal; 2021 May; 199():114048. PubMed ID: 33836461
[TBL] [Abstract][Full Text] [Related]
16. Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.
Kawakami E; Tabata J; Yanaihara N; Ishikawa T; Koseki K; Iida Y; Saito M; Komazaki H; Shapiro JS; Goto C; Akiyama Y; Saito R; Saito M; Takano H; Yamada K; Okamoto A
Clin Cancer Res; 2019 May; 25(10):3006-3015. PubMed ID: 30979733
[TBL] [Abstract][Full Text] [Related]
17. Identification of metabolic biomarkers for diagnosis of epithelial ovarian cancer using internal extraction electrospray ionization mass spectrometry (iEESI-MS).
Li J; Wang Z; Liu W; Tan L; Yu Y; Liu D; Wei Z; Zhang S
Cancer Biomark; 2023; 37(2):67-84. PubMed ID: 37248885
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Buas MF; Gu H; Djukovic D; Zhu J; Drescher CW; Urban N; Raftery D; Li CI
Gynecol Oncol; 2016 Jan; 140(1):138-44. PubMed ID: 26521694
[TBL] [Abstract][Full Text] [Related]
19. The Lipidomic Analyses in Low and Highly Aggressive Ovarian Cancer Cell Lines.
Zhao Z; Cai Q; Xu Y
Lipids; 2016 Feb; 51(2):179-87. PubMed ID: 26661829
[TBL] [Abstract][Full Text] [Related]
20. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]